Delcath Systems, Inc : DELCATH ANNOUNCES POSTING OF BRIEFING DOCUMENTS FOR FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING ON

Delcath Systems, Inc : DELCATH ANNOUNCES POSTING OF BRIEFING DOCUMENTS FOR FDA
         ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING ON MELBLEZTM KIT

QUEENSBURY,NY-April 30,2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today
announced that the U.S. Food and Drug Administration (FDA) has published on
its website the briefing documents for the upcoming May 2, 2013 Oncologic
Drugs Advisory Committee (ODAC) meeting. The ODAC will review Delcath's New
Drug Application (NDA) for the marketing approval of Melblez^TM Kit (Melblez
(melphalan) for Injection for use with the Delcath Hepatic Delivery System),
the Company's proprietary drug/device combination product for the treatment of
patients with unresectable ocular melanoma metastatic to the liver.

In addition to the briefing materials, the FDA plans to provide a live webcast
of the meeting. The briefing materials from Delcath and the FDA, and
information regarding the webcast including the web address for the webcast,
can be accessed on the FDA webpage at:
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm341089.htm

About Oncologic Drugs Advisory Committee Meetings

    The FDA's Oncologic Drugs Advisory Committee (ODAC) consists of a
panel of independent experts who advise the FDA on the safety and efficacy of
proposed new cancer therapies, and specific questions raised by the FDA as the
agency considers regulatory decisions. The FDA is not bound by the committee's
recommendation, but the agency takes its advice into consideration when
reviewing new drug applications.

AboutDelcathSystems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic exposure of those agents. The Company's
initial focus is on the treatment of primary and metastatic liver cancers. In
2010, Delcath announced that its randomized Phase 3 clinical trial for
patients with metastatic melanoma in the liver had successfully achieved the
study's primary endpoint of extended hepatic progression-free survival. The
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United States, our proprietary product to deliver and filter
melphalan hydrochloride is marketed under the trade name Delcath Hepatic
CHEMOSAT^® Delivery System (CHEMOSAT Delivery System for Melphalan.) The
Company obtained authorization to affix a CE Mark for the Generation Two
CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the
CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in Europe. In October 2012, the Company satisfied all of the
requirements to affix the CE Mark to the Hepatic CHEMOSAT Delivery System
device for intra-hepatic arterial delivery and extracorporeal filtration of
doxorubicin hydrochloride injection (CHEMOSAT Delivery System for
Doxorubicin). The Company has not yet received FDA approval for commercial
sale of its system in the United States. The Company's NDA has been accepted
for filing and substantive review by the FDA. For more information, please
visit the Company's website at www.delcath.com. 

Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the outcome of the ODAC meeting and
the impact, if any, of the advisory panel's recommendation on the FDA's
decision regarding the Company's new drug application (NDA), timing of
completion of the FDA's review of our NDA, the extent to which the FDA may
request additional information or data and our ability to provide the same in
a timely manner, additional extensions to the PDUFA date by the FDA,
acceptability of the Phase 1, 2 and 3 clinical trial data by the FDA, FDA
approval of the Company's NDA for the treatment of ocular metastatic melanoma
to the liver, adoption, use and resulting sales, if any, in the United States,
adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver
and filter melphalan in the EEA, our ability to successfully commercialize the
chemosaturation system and the potential of the chemosaturation system as a
treatment for patients with primary and metastatic disease in the liver,
market acceptance of the Gen Two CHEMOSAT system and patient outcomes using
the same, approval of the current or future chemosaturation system for
delivery and filtration of melphalan, doxorubicin or other chemotherapeutic
agents for various indications in the US and/or in foreign markets, actions by
the FDA or other foreign regulatory agencies, our ability to successfully
enter into strategic partnership and distribution arrangements in foreign
markets including Australia and key Asian markets and timing an revenue, if
any, of the same, the approval of the Hepatic CHEMOSAT Delivery System device
to deliver and filter doxorubicin in key Asian markets and patient outcomes
using the same, our ability to obtain reimbursement for the CHEMOSAT system,
uncertainties relating to the timing and results of research and development
projects, uncertainties relating to the timing and results of future clinical
trials, and uncertainties regarding our ability to obtain financial and other
resources for any research, development and commercialization activities.
These factors, and others, are discussed from time to time in our filings with
the Securities and Exchange Commission. You should not place undue reliance on
these forward-looking statements, which speak only as of the date they are
made. We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the date
they are made.

ContactInformation:
Investor Contact:           Media Contact:
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                   EVC Group
646-445-4801/951-316-0577   646-201-5431

###

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
HUG#1697996